Treatment of Advanced Non-small Cell Lung Cancer with Extracorporeal High Frequency Thermotherapy Co

来源 :Chinese Journal of Integrative Medicine | 被引量 : 0次 | 上传用户:swfcmoon
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Objective: To observe the clinical efficacy and benefit response of extracorporeal high frequency thermotherapy (EHFT) combined with Chinese medicine (CM) in the treatment of patients with advanced non-small cell lung cancer. Methods: The study adopted a prospective, small sample and randomized controlled method, and the advanced non-small cell lung cancer patients were assigned to two groups according to the table of random digits, one having the treatment of EHFT combined with CM (the treatment group), the other only with CM (the control group). The patients in the treatment group were treated with EHFT one hour once per day, together with CM differentiation decoction, 250 mL orally taken, twice daily for 14 days as one cycle, and 3-4 cycles was performed. The patients in the control group were treated only with CM differentiation decoction using the same dose as the treatment group. The efficacies were evaluated after three to four cycles of treatment. Primary endpoints were disease control rate (DCR) and time to progression (TTP). Secondary endpoints were overall survival time and 1-year survival rate. Results: Sixty-six patients accomplished the study. After the patients underwent different treatments, none of the patients got a complete response or partial response in both groups. In the treatment group, DCR was 72.2%, and 10 had progression of disease (28.8%), while the DCR of the control group was 63.3%, and 11 had progression of disease (36.7%); there was a significant statistical difference (P<0.05), suggesting that the combined regimen had superiority on the DCR. As for long-term efficacy, the median survival time (MST) of the treatment group was 7.5 months, TTP was 5.5 months, and 1-year survival rate was 21.4 %; in the control group, the results were 6.8 months, 4.5 months and 16.6% respectively. There was significant statistical difference on TTP (P<0.05), but no difference on MST or 1-year survival rate. Conclusion: EHFT combined with CM differentiation has better tolerance and short-term efficacy in the treatment of patients with advanced NSCLC. Objective: To observe the clinical efficacy and benefit response of extracorporeal high frequency thermotherapy (EHFT) combined with Chinese medicine (CM) in the treatment of patients with advanced non-small cell lung cancer. Methods: The study adopted a prospective, small sample and randomized controlled method, and the advanced non-small cell lung cancer patients were assigned to two groups according to the table of random digits, one having the treatment of EHFT combined with CM (the treatment group), the other only with CM (the control The patients in the treatment group were treated with EHFT one hour once per day, together with CM differentiation decoction, 250 mL orally taken, twice daily for 14 days as one cycle, and 3-4 cycles was performed. The patients in the control group were treated only with CM differentiation decoction using the same dose as the treatment group. The efficacies were evaluated after three to four cycles of treatment. Primary endpoints were disease Secondary endpoints were overall survival time and 1-year survival rate. Results: Sixty-six patients accomplished the study. After the patients underwent different treatments, none of the patients got a complete DCR was 72.2%, and 10 had progression of disease (28.8%), while the DCR of the control group was 63.3%, and 11 had progression of disease (36.7%). suggesting that the combined regimen had superiority on the DCR. As for long-term efficacy, the median survival time (MST) of the treatment group was 7.5 months, TTP was 5.5 months , and 1-year survival rate was 21.4%; in the control group, the results were 6.8 months, 4.5 months and 16.6% respectively. There was a significant statistical difference on TTP (P <0.05) year survival rate. Conclusion: EHFT combined with CM differentiation has better tolerance and short-term efficacy in the treatment of patients with advanced NSCLC.
其他文献
目的比较GP方案与NP方案治疗晚期非小细胞肺癌的疗效和毒性反应。方法56例晚期非小细胞肺癌随机分为两组,GP组29例,吉西他滨1.0~1.2g/m2,第1、第8天,静脉滴注;顺铂25mg/m2,第1
答:可以通过以下几种方法掌握充灌量 1、制冷设备一般都有额定电流标称值,我们可以把电流钳表钳入电路,边加制冷剂,边看表,加到接近或达到标称电流值时,关闭加液阀,运行10分
采用幽门弹簧插入配合灌胃10%高渗盐水及65℃热糊复制大鼠胃癌癌前病变模型,观察胃炎消对其胃液pH值、胆酸含量及组织病理学变化的影响。结果,大、小剂量的胃炎消皆能降低模型大鼠胃液
目的:通过头颅三维断层标本与MRI对照研究三叉神经桥池段,为影像学诊断提供解剖学依据。方法:利用头颅三维连续断层标本35套、正常成人头颅MR检查103例和增强MR检查36例,观察和测量三叉神经桥池
1 高血压夏枯草1000g,放大蒸锅中煎3次去渣取汁,加适量蜂蜜熬成膏入冰箱冷藏,每日早晚各一匙,温开水送服,能使血压持久稳定于正常范围.夏枯草清肝火,散郁结,治头痛,故对高血
楚氏接骨膏原名“金创接骨膏”,是楚氏伤科祖传秘方。临床上用于治疗闭合性骨折疗效满意。本实验通过在兔开放性伤口上外敷楚氏接骨膏,观察其对创伤的修复作用,以探讨将该膏
1 材料与方法1.1 动物及分组 选用健康、雄性Wistar大鼠(由黑龙江中医药大学实验动物室提供)34只,体重为100g~200g,随机分成4组;空白组5只,模型组5只,治疗组12只,对照组12只
单克隆抗体的临床治疗作用早已被人们所认识,由于是通过反常规和外源性的方式使人体获得免疫抗体,所以第一个单克隆抗体是从小鼠制得的。但是以此种方式制得的鼠源性抗体会
水,对中药材有较强的穿透力,可溶解中药材中的生物碱、甙类、有机酸、鞣质、蛋白质、糖类、多糖类和无机盐等有效成分,是煎煮中药的最常用溶媒。在实践中,笔者观察到煎药用水的质
本文介绍了作者利用自行设计的剪切力流动室对大鼠脑微血管内皮细胞在剪切力作用下的形态学改变进行了研究,在此基础上又进行了剪切力对内皮细胞骨架蛋白结构作用的研究,为进一步开展剪切力对微血管内皮细胞功能,代谢等方面的影响提供了实验数据.